1
|
Tiera MJ, Martins GO, Júnior AMM, Petrônio MS, Mello LR, Han SW. AMPHIPATHIC CHITOSANS AS VECTORS FOR SIRNA DELIVERY. Cytotherapy 2021. [DOI: 10.1016/j.jcyt.2021.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
2
|
Cho GJ, Lee KM, Kim HY, Han SW, Oh MJ, Chiec L, Chae YK. Postpartum haemorrhage requiring transfusion and risk of cardiovascular disease later in life: a retrospective cohort study. BJOG 2020; 128:738-744. [PMID: 32946626 DOI: 10.1111/1471-0528.16515] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/11/2020] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To determine whether postpartum haemorrhage (PPH) is associated with cardiovascular disease (CVD), including cerebrovascular and ischaemic heart disease beyond the peripartum period. DESIGN Population-based cohort study. SETTING Merged databases of the Korea National Health Insurance (KNHI) claims, National Health Screening Examination and National Health Screening Program for Infants and Children. POPULATION Women who gave birth in 2007 in the Republic of Korea and who were tracked through to 2015 for the occurrence of CVD. METHODS Patients were identified and the occurrences of PPH and transfusion were determined using the KNHI claims database. The occurrence of CVD was tracked through 2015 using codes from the International Classification of Diseases, tenth revision (ICD-10). MAIN OUTCOME MEASURES The risk of CVD after PPH. RESULTS Among 150 381 women who gave birth during the study period, 9107 were diagnosed with PPH and 899 were treated with transfusion. The risk of CVD in women with PPH was no different than in women without PPH, after adjustment (HR 1.03, 95% CI 0.93-1.13). The risk of CVD in women with PPH requiring transfusion was significantly increased compared with women without PPH, after adjustment (HR 1.60, 95% CI 1.25-2.06). The risk of CVD in women with PPH without transfusion was not significantly different compared with women without PPH (HR 0.96, 95% CI 0.86-1.07). CONCLUSIONS Postpartum haemorrhage (PPH) requiring transfusion is associated with an increased risk of CVD. Guidelines for management should be established, and further studies on the mechanisms involved should be conducted. TWEETABLE ABSTRACT PPH requiring transfusion is associated with an increased risk of CVD.
Collapse
Affiliation(s)
- G J Cho
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea.,Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - K-M Lee
- School of Industrial Management Engineering, Korea University, Seoul, Korea
| | - H Y Kim
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea
| | - S W Han
- School of Industrial Management Engineering, Korea University, Seoul, Korea
| | - M-J Oh
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea
| | - L Chiec
- Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Y K Chae
- Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.,Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
| |
Collapse
|
3
|
Cho BH, Cheon K, Lee KY, Jung YH, Han SW, Park JH, Choi HY, Cho HJ, Park HJ, Nam HS, Heo JH, Lee HS, Kim S, Kim YD. Association between body mass index and stroke severity in acute ischaemic stroke with non-valvular atrial fibrillation. Eur J Neurol 2020; 27:1672-1679. [PMID: 32392368 DOI: 10.1111/ene.14304] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2020] [Accepted: 04/30/2020] [Indexed: 01/22/2023]
Abstract
BACKGROUND AND PURPOSE The objective of this study was to investigate the association between body mass index (BMI) and both initial stroke severity at presentation and functional outcomes after acute ischaemic stroke (AIS) in patients with non-valvular atrial fibrillation (NVAF). METHODS Patients were categorized on the basis of their BMI into underweight (BMI <18.5, n = 111), normal (18.5 ≤ BMI <25, n = 1036) and overweight to obese (BMI ≥25, n = 472) groups. Initial stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) score and functional outcomes were assessed using the modified Rankin Scale score at discharge. The differences in stroke severity and functional outcomes were compared between groups using robust log-linear regression with a Poisson distribution and binary logistic regression analysis. RESULTS A total of 1619 AIS patients with NVAF from six hospitals were included. Compared with the NIHSS scores [median 5, interquartile range (IQR) 2-14] of normal-weight patients, the NIHSS scores (median 9, IQR 4-19) of underweight patients were more likely to be higher, whereas those of overweight to obese patients were lower (median 4, IQR 1-12) (P < 0.001). In terms of functional outcomes after stroke, underweight patients had a higher risk of poor functional outcomes (odds ratio 1.78, 95% confidence interval 1.09-2.56, P = 0.01) but overweight to obese patients had no significant difference in functional outcomes compared with normal-weight patients. CONCLUSION An inverse association was found between BMI and stroke severity in AIS patients with NVAF. This suggests the presence of an obesity paradox for short-term outcomes in patients with NVAF.
Collapse
Affiliation(s)
- B-H Cho
- Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.,Department of Neurology, Gangnam Severance Hospital, Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, Korea
| | - K Cheon
- Department of Neurology, Gangnam Severance Hospital, Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, Korea
| | - K-Y Lee
- Department of Neurology, Gangnam Severance Hospital, Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, Korea
| | - Y H Jung
- Department of Neurology, Gangnam Severance Hospital, Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, Korea.,Department of Neurology, Changwon Fatima Hospital, Changwon, Korea
| | - S W Han
- Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
| | - J H Park
- Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
| | - H-Y Choi
- Department of Neurology, Kyung Hee University School of Medicine, Kyung Hee University Hospital, Gangdong, Seoul, Korea
| | - H-J Cho
- Department of Neurology, Pusan National University Hospital, Pusan National University College of Medicine and Biomedical Research Institute, Busan, Korea
| | - H J Park
- Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.,Department of Neurology, Brain Research Institute, Keimyung University School of Medicine, Daegu, Korea
| | - H S Nam
- Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
| | - J H Heo
- Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
| | - H S Lee
- Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Korea
| | - S Kim
- Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Korea
| | - Y D Kim
- Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|
4
|
Cho GJ, Choi S, Lee K, Han SW, Kim HY, Ahn K, Hong S, Kim H, Oh M. Women with threatened preterm labour followed by term delivery have an increased risk of spontaneous preterm birth in subsequent pregnancies: a population‐based cohort study. BJOG 2019; 126:901-905. [DOI: 10.1111/1471-0528.15653] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/02/2019] [Indexed: 11/30/2022]
Affiliation(s)
- GJ Cho
- Department of Obstetrics and Gynaecology Korea University College of Medicine Seoul Korea
| | - S‐J Choi
- Department of Obstetrics and Gynaecology Samsung Medical Centre Sungkyunkwan University School of Medicine Seoul Korea
| | - K‐M Lee
- School of Industrial Management Engineering Korea University Seoul Korea
| | - SW Han
- School of Industrial Management Engineering Korea University Seoul Korea
| | - HY Kim
- Department of Obstetrics and Gynaecology Korea University College of Medicine Seoul Korea
| | - K‐H Ahn
- Department of Obstetrics and Gynaecology Korea University College of Medicine Seoul Korea
| | - S‐C Hong
- Department of Obstetrics and Gynaecology Korea University College of Medicine Seoul Korea
| | - H‐J Kim
- Department of Obstetrics and Gynaecology Korea University College of Medicine Seoul Korea
| | - M‐J Oh
- Department of Obstetrics and Gynaecology Korea University College of Medicine Seoul Korea
| |
Collapse
|
5
|
An E, Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci DVT, Oh DY, Bang YJ. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Ann Oncol 2017; 28:110-115. [PMID: 27687309 PMCID: PMC5378223 DOI: 10.1093/annonc/mdw442] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC have yet to show efficacy in clinical trials. These findings raise question about the ability of standard HER2 diagnostics to accurately distinguish between GC patients who would and would not benefit from anti-HER2 therapies. Patients and methods GC patients (n = 237), including a subset from the Trastuzumab in GC (ToGA) trial were divided into three groups based on HER2 status and history of treatment with standard chemotherapy or chemotherapy plus trastuzumab. We applied mass spectrometry-based proteomic analysis to quantify HER2 protein expression in formalin-fixed tumor samples. Using HER2 expression as a continuous variable, we defined a predictive protein level cutoff to identify which patients would benefit from trastuzumab. We compared quantitated protein level with clinical outcome and HER2 status as determined by conventional HER2 diagnostics. Results Quantitative proteomics detected a 115-fold range of HER2 protein expression among patients diagnosed as HER2 positive by standard methods. A protein level of 1825 amol/µg was predicted to determine benefit from the addition of trastuzumab to chemotherapy. Trastuzumab treated patients with HER2 protein levels above this cutoff had twice the median overall survival (OS) of their counterparts below the cutoff (35.0 versus 17.5 months, P = 0.011). Conversely, trastuzumab-treated patients with HER2 levels below the cutoff had outcomes similar to HER2-positive patients treated with chemotherapy. (Progression-free survival = 7.0 versus 6.5 months: P = 0.504; OS = 17.5 versus 12.6 months: P = 0.520). HER2 levels were not prognostic for response to chemotherapy. Conclusions Proteomic analysis of HER2 expression demonstrated a quantitative cutoff that improves selection of GC patients for trastuzumab as compared with current diagnostic methods.
Collapse
Affiliation(s)
- E An
- NantOmics, Rockville, USA,Oncoplex Diagnostics, Rockville, USA
| | - C-Y Ock
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, Korea
| | - T-Y Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, Korea
| | - K-H Lee
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Seoul, Korea
| | - S-W Han
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Seoul, Korea
| | - S-A Im
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Seoul, Korea
| | - T-Y Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Seoul, Korea
| | - W-L Liao
- NantOmics, Rockville, USA,Oncoplex Diagnostics, Rockville, USA
| | - F Cecchi
- NantOmics, Rockville, USA,Oncoplex Diagnostics, Rockville, USA
| | - A Blackler
- NantOmics, Rockville, USA,Oncoplex Diagnostics, Rockville, USA
| | - S Thyparambil
- NantOmics, Rockville, USA,Oncoplex Diagnostics, Rockville, USA
| | - W H Kim
- Department of Pathology, Seoul National University Hospital, Seoul, Korea
| | - J Burrows
- Oncoplex Diagnostics, Rockville, USA
| | - T Hembrough
- NantOmics, Rockville, USA,Oncoplex Diagnostics, Rockville, USA
| | - D V T Catenacci
- Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA
| | - D-Y Oh
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Seoul, Korea
| | - Y-J Bang
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Seoul, Korea
| |
Collapse
|
6
|
Lim J, Lee KH, Min A, Kim SG, Kim JE, Kim TY, Han SW, Oh DY, Kim TY, Lim SA. Abstract P1-02-05: Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-02-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PIK3CA) is one of the most commonly mutated genes in breast cancer. But the prognostic and predictive role of PIK3CA mutations remains a matter of debate. It has been suggested that PIK3CA mutations are related to resistance to trastuzumab-based therapies, but they were also related to relatively indolent disease with better progression-free survival. Recently, circulating tumor DNA has been proposed to be a sensitive biomarker for detecting the presence of specific genetic aberrations in various cancer types, providing prognostic and predictive information. In this study, we evaluated prognostic and predictive role of PIK3CA mutations in patients with HER2-positive metastatic breast cancer treated with 1st line trastuzumab and taxane combination chemotherapy.
Thirty-four patients with blood samples obtained before 1st line trastuzumab and taxane combination chemotherapy were included in the study. We analyzed two PIK3CA hotspot mutations (E545K, H1047R) in ctDNA by digital droplet PCR (RaindropTM). The samples were collected from April 2005 to December 2011, centrifuged and stored as plasma, and were analyzed in 2015, after 4-10 years of storage period.
Median age was 47 years (range: 31 to 75 years), and histologic type of cancer was ductal carcinoma in all cases. PIK3CA mutations were detected in 21 (61.8%) of 34 patients. Patients with mutated PIK3CA in ctDNA had longer progression-free survival (PIK3CA wild type vs mutant, 11.0 months vs 22.0 months; P = 0.013). In hormone receptor positive group, patients with mutated PIK3CA had longer progression-free survival (PIK3CA wild type vs mutant, 12 months vs 18 months, P=0.17). Patients with PIK3CA mutations had a lower objective response rate than patients with wild-type, but there was no statistical significance (CR+PR; PIK3CA wild type vs mutant, 84.6% vs 66.7%, P=0.43). There was no significant difference in response rate (P = 0.48) or PIK3CA mutational status (P = 0.44) according to hormonal receptor status (estrogen receptor and/or progesterone receptor).
In conclusion, PIK3CA mutations were frequently detected by digital PCR from ctDNA of patients with HER2-positive breast cancer and they were related to significantly better PFS. We plan to analyze the PIK3CA mutation status in matched tumor tissue.
Citation Format: Lim J, Lee K-H, Min A, Kim S-G, Kim J-E, Kim T-Y, Han S-W, Oh D-Y, Kim T-Y, Lim S-A. Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-02-05.
Collapse
Affiliation(s)
- J Lim
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - K-H Lee
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - A Min
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - S-G Kim
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - J-E Kim
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - S-W Han
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - D-Y Oh
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - S-A Lim
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| |
Collapse
|
7
|
Qi Q, Pan YF, Shen JJ, Gu XQ, Han SW, Liao HH, Jiang YZ, Zhong LP. Circulating DNA for detection of gastric cancer. Eur Rev Med Pharmacol Sci 2016; 20:2558-2564. [PMID: 27383305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
OBJECTIVE Gastric cancer (GC) is one of the most common malignant tumors worldwide, particularly, prevalent in China. Despite the decreasing incidence of GC in China, the 5-year survival rate is still not over 30% yet. Therefore, early diagnosis and therapeutic outcome evaluation of GC remains as the issue to be resolved in a clinical setting. MATERIALS AND METHODS Recent studies have found the presence of a certain amount of circulating DNA in the peripheral blood of patients with malignant tumor and shown that these free DNA bear tumor-specific genetic information. The circulating DNA detection includes quantitative and qualitative methods and analysis. Combined monitoring of changes in circulating DNA levels and aberrant alteration of relevant tumor genes is likely to provide comprehensive real-time information to patients. RESULTS Under normal conditions, oncogene presents in the form of proto-oncogene such as K-ras, which is in non-carcinogenic status under the influence of tumor suppressor gene. When tumor suppressor gene is damaged or mutated of oncogene itself is induced for instance P53, oncogene is then activated and induces tumorigenesis. However, compared to gene mutation detection, the detection of DNA methylation is relatively more well-developed and stable. CONCLUSIONS This article reviews the current status of the research on circulating DNA in the diagnosis, assessment of response to therapy and prognostic evaluation in GC. In addition, the advantage, current issue and prospect of using circulating DNA as tumor marker are also analyzed.
Collapse
Affiliation(s)
- Q Qi
- Department of Oncology, Huzhou Central Hospital, Huzhou, China.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Kim MH, Im YJ, Kil HK, Han SW, Joe YE, Lee JH. Impact of caudal block on postoperative complications in children undergoing tubularised incised plate urethroplasty for hypospadias repair: a retrospective cohort study. Anaesthesia 2016; 71:773-8. [PMID: 27156500 DOI: 10.1111/anae.13463] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/21/2016] [Indexed: 11/26/2022]
Abstract
This study aimed to assess the association between caudal block and postoperative complications after tubularised incised plate urethroplasty. The medical records of 388 paediatric patients who underwent urethroplasty at a tertiary medical centre were analysed retrospectively. Among the 342 patients included, 216 patients received a caudal block and 72 (21.1%) patients suffered surgical complications. The number of patients having surgical complications was significantly greater among patients who received a caudal block than among patients who did not receive a caudal block (53 (24.5%) versus 19 (15.1%), respectively, p = 0.04). Based on multivariate logistic regression analysis, duration of surgery, caudal block and hypospadias types were independent risk factors for the surgical complications. Patients with caudal block had an odds ratio of 2.1 (95% CI, 1.14-3.81, p = 0.018) for the development of postoperative complications compared with patients without caudal block. This analysis demonstrates that caudal block is associated with surgical complications after tubularised incised plate urethroplasty.
Collapse
Affiliation(s)
- M H Kim
- Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Y J Im
- Department of Urology, Seoul National University Children's Hospital, Seoul, Republic of Korea
| | - H K Kil
- Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - S W Han
- Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Y E Joe
- Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - J H Lee
- Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
9
|
Suh KJ, Ryu HS, Lee KH, Im SA, Kim TY, Kim H, Yang Y, Moon HG, Han SW, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ. Abstract P4-07-08: The prognostic significance of ataxia-telangiectasia-mutated (ATM) and p53 expression in breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-07-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The purpose of this study was to investigate the correlation of ataxia-telangiectasia-mutated (ATM) protein and p53 expression with clinicopathological features and prognosis in patients with sporadic breast cancers. The expression of ATM and p53 was determined by immunohistochemistry in 420 surgically resected breast cancers. Loss of ATM was observed in 126 out of 407 evaluable cases (31.0%), and was significantly associated with aggressive features with large tumor size, lymph node metastasis, higher tumor grade, and negativity of ER and/or PR. ATM loss was associated with a significantly shorter disease-free survival (DFS) (p = 0.019). Abnormal p53 expression was found in 39.3% of tumors (157 out of 400), conferring a worse DFS as well (p = 0.002). When investigated together, combined ATM and p53 expression status were associated with a worse DFS (p = 0.002). On multivariate analysis, ATM loss and abnormal p53 expression status was an independent predictor of poorer DFS (intact ATM and normal p53 vs. ATM loss and abnormal p53, HR 3.350; 95% CI 1.496 - 7.502; p = 0.003). Furthermore, in patients treated with adjuvant anthracyclines, either p53 alone or p53 combined with ATM significantly influenced DFS (p = 0.004, p = 0.015, respectively). The present study demonstrates that expression of ATM and p53 is an independent prognostic marker in breast cancers, and might be a practical tool for predicting benefits from anthracycline-based adjuvant therapy.
Citation Format: Suh KJ, Ryu HS, Lee K-H, Im S-A, Kim T-Y, Kim H, Yang Y, Moon H-G, Han S-W, Oh D-Y, Han W, Kim T-Y, Park IA, Noh D-Y, Bang Y-J. The prognostic significance of ataxia-telangiectasia-mutated (ATM) and p53 expression in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-07-08.
Collapse
Affiliation(s)
- KJ Suh
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - HS Ryu
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - K-H Lee
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - S-A Im
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - H Kim
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - Y Yang
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - H-G Moon
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - S-W Han
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - D-Y Oh
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - W Han
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - IA Park
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - D-Y Noh
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| | - Y-J Bang
- Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea
| |
Collapse
|
10
|
Im SA, Kim JH, Lee KH, Kim SH, Oh DY, Kim YJ, Han SW, Kim TY, Kim TY, Jung J, Bang YJ. Abstract P4-13-19: Poziotinib, an oral, irreversible pan-HER inhibitor, demonstrates promising clinical activity in metastatic HER2 positive breast cancer patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Poziotinib is a novel, oral, irreversible pan-HER inhibitor that has been studied in two completed Phase 1 clinical trials in patients with advanced solid tumors (HM-PHI-101; HM-PHI-102) and is currently being studied in several Phase 2 clinical trials. Preclinical studies have shown poziotinib to be more potent in vitro than other EGFR- and HER2-directed tyrosine kinase inhibitors. This study collates the clinical experience of poziotinib in patients with advanced HER2 positive breast cancer from the two completed Phase 1 trials.
Results:
The maximum tolerated dose (MTD) and safety of poziotinib were evaluated in HM-PHI-101 (once daily, Day 1-14 q3 weeks) and in HM-PHI-102 (continuous dosing). The Dose Limiting Toxicity (DLT) was diarrhea in both studies. Anti-diarrheal medicine was allowed, but prophylactic anti-diarrheal therapy was not used. The most frequently reported Grade 3 AE was diarrhea (40%). The MTD for intermittent dosing of poziotinib was 24 mg and the MTD for continuous dosing was 16 mg. The Dose Limiting Toxicity (DLT) was diarrhea in both studies. Anti-diarrheal medicine was allowed, but prophylactic anti-diarrheal therapy was not used. In total, 10 patients with HER2 positive metastatic breast cancer were treated in the two trials (median age 56.5, range 30-69). These patients were heavily pretreated (median number of previous treatment regimens 5, range 3-9), and all patients had failed treatment with both trastuzumab and lapatinib. The Overall Response Rate (ORR) in these breast cancer patients was 60% and Clinical Benefit Rate (CBR) was 80%. The median duration of response was 32.5 weeks (range 18 - 56 weeks). Two patients in the early dose cohorts of 1 or 2mg had progressive disease. The median progression free survival (PFS) was 28 weeks (6, 6, 12, 17, 25, 31, 37, 49, 57, and 98 weeks).
Conclusions:
Poziotinib showed very promising clinical activity in Phase 1 patients with metastatic HER2 positive breast cancer, who had been heavily pretreated and failed two prior HER2-directed therapies. The ORR in this patient population was 60% and the CBR was 80% in these two early dose finding studies. The AEs observed in these studies was consistent with other pan-HER and EGFR inhibitors. While the majority of DLT cases involves diarrhea, toxicity of other adverse events was relatively tolerable. An intermittent dosing schedule seemed appropriate for poziotinib. Multiple Phase 2 studies with poziotinib are ongoing in patients with breast cancer and other solid tumors.
Citation Format: Im S-A, Kim J-H, Lee K-H, Kim SH, Oh D-Y, Kim Y-J, Han S-W, Kim T-Y, Kim T-Y, Jung J, Bang Y-J. Poziotinib, an oral, irreversible pan-HER inhibitor, demonstrates promising clinical activity in metastatic HER2 positive breast cancer patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-19.
Collapse
Affiliation(s)
- S-A Im
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - J-H Kim
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - K-H Lee
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - SH Kim
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - D-Y Oh
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - Y-J Kim
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - S-W Han
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - J Jung
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - Y-J Bang
- Seoul National University Hospital, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| |
Collapse
|
11
|
Yang Y, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, Han W, Moon HG, Park IA, Noh DY, Im SA. Abstract P1-10-11: Prognostic value of non-alcoholic fatty liver disease in stage II/III breast cancer patients who received neoadjuvant chemotherapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-10-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Metabolic syndrome is associated with various malignancies, including breast cancer. Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome. NAFLD is frequently observed during chemotherapy, but its clinical implication is unclear. The purpose of this study is to evaluate the prognostic value of NAFLD in patients with stage II/III breast cancer who received neoadjuvant chemotherapy (NAC Tx).
Methods
The patients with clinical stage II/III breast cancer who received NAC Tx with docetaxel and doxorubicin were enrolled. Treatment sequences were: 3 cycles of NAC Tx → surgery → 3 cycles of adjuvant chemotherapy (AC Tx), or 6 cycles of NAC Tx → surgery, allowing AC Tx at the physician's discretion. NAFLD was determined by ultrasonography (radiologists' decision), non-constrast computed tomography [CT] (the attenuation of liver is less than that of spleen or <49 hounsfield unit [HU]) or contrast CT (the difference between liver and spleen attenuation < -18.5 HU). The presence of NAFLD was evaluated 3 times, at diagnosis, after NAC Tx and after the completion of AC Tx. Improvement of NAFLD was defined as the disappearance of NAFLD after NAC Tx.
Results
Between 2002 and 2008, 269 patients were enrolled. The median age was 45 (range 18-69), and 51.7% and 28.6% were with hormone receptor and HER2 positive tumors, respectively. The median number of NAC Tx was 3 cycles (range 1-6). NAFLD was observed in 33 (12.4%) patients at diagnosis, 52 (19.3%) after NAC Tx and 71 (26.4%) at the completion of AC Tx. The patients with NAFLD at diagnosis showed shorter overall survival than those without NAFLD (HR=2.688, 95% CI 1.259-5.747, P=0.011). The improvement of NAFLD during NAC Tx was observed in 28 (10.4%, group A) and persistence of NAFLD observed in 24 (8.9%, group B). Group A showed better prognosis in both PFS (HR 0.125, 95 % CI 0.016-0.962) and OS (no event), whereas group B showed worse PFS (HR 2.329, 95% CI 1.280-4.237) and OS (HR 3.721, 95% CI 1.727-8.015) compared to the patients without NAFLD at diagnosis.
Conclusions
NAFLD at diagnosis was a poor prognostic marker of OS in patients who received NAC Tx. Improvement of NAFLD during NAC TX was associated with good prognosis in terms of PFS and OS.
Citation Format: Yang Y, Lee K-H, Kim T-Y, Han S-W, Oh D-Y, Kim T-Y, Han W, Moon H-G, Park IA, Noh D-Y, Im S-A. Prognostic value of non-alcoholic fatty liver disease in stage II/III breast cancer patients who received neoadjuvant chemotherapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-11.
Collapse
Affiliation(s)
- Y Yang
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - K-H Lee
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - S-W Han
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - D-Y Oh
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - W Han
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - H-G Moon
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - IA Park
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - D-Y Noh
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| | - S-A Im
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Korea
| |
Collapse
|
12
|
Jang JE, Kim HP, Lee SH, Lee DW, Lim YJ, Han SW, Kim TY. Abstract A28: NFATC3-PLA2G15 fusion transcript identified by RNA-sequencing promotes tumor progression in colorectal cancer cells. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-a28] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In order to identify novel fusion transcripts in colorectal cancer, we carried out paired-end RNA sequencing in 28 human colorectal cancer cell lines. Fusion transcript candidates were identified using ChimeraScan and FusionMap tools. We obtained 1380 candidates having 4 or more read counts and spanning reads. Among the candidates, we selected 27 candidates for validation which harbors genes related to the Wnt signaling pathway or kinases according to KEGG or DAVID. After the targeted gene filtering step, validation using RT-PCR with fusion specific primers finally resulted in 2 intra- and 1 inter-fusion transcripts. Intra-fusion transcripts were NFATC3-PLA2G15 and AKAP13-PDE8A and inter-fusion transcript was KRT8-PKM2 each identified in colo-320, SW-480 and SNU-1235, respectively. The fusion junctions were confirmed by Sanger sequencing. NFATC3-PLA2G15 fusion transcripts consisted of exon 1-9 of NFATC3 (nuclear factor of activated T-cells, cytoplasmic 3) gene and exon 2-6 of the PLA2G15 (Phospholipase A2, Group 5) gene and both located on the same chromosome 16q. NFATC3 is known as transcription factor in the Wnt signaling pathway and regulates function of the target genes like cell proliferation, invasion and epithelial-to-mesenchymal transition (EMT). Under the experiments using siRNA in the colo-320 cell carrying fusion transcript, knockdown of the NFATC3-PLA2G15 fusion transcript decreased mRNA and protein expression of mesenchymal markers, namely vimentin (VIM), Twist-related protein 1 (TWIST1) and fibronectin (FN), and increased epithelial markers, E-cadherin (CDH1) and claudin-1 (CLDN1). Fusion transcripts knockdown also led to decrease of the invasion ability regulated by above markers. Moreover, soft agar assay showed inhibition of colony formation after fusion transcript knockdown. Fusion transcript downregulation also resulted in decrease of cell proliferation and mRNA and protein expression of cyclin D but increase in p27 level. The knockdown did not have influence in the fusion negative cell line. Collectively, these results suggest that the NFATC3-PLA2G15 fusion transcript is involved in invasion and proliferation of colorectal cancer cells.
Citation Format: JE Jang, HP Kim, SH Lee, DW Lee, YJ Lim, SW Han, TY Kim. NFATC3-PLA2G15 fusion transcript identified by RNA-sequencing promotes tumor progression in colorectal cancer cells. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A28.
Collapse
Affiliation(s)
- JE Jang
- 1Cancer Research Institute Seoul National University College of Medicine, seoul, Korea, Republic of
| | - HP Kim
- 1Cancer Research Institute Seoul National University College of Medicine, seoul, Korea, Republic of
| | - SH Lee
- 1Cancer Research Institute Seoul National University College of Medicine, seoul, Korea, Republic of
| | - DW Lee
- 2Department of Internal Medicine, Seoul National University Hospital, seoul, Korea, Republic of
| | - YJ Lim
- 2Department of Internal Medicine, Seoul National University Hospital, seoul, Korea, Republic of
| | - SW Han
- 2Department of Internal Medicine, Seoul National University Hospital, seoul, Korea, Republic of
| | - TY Kim
- 2Department of Internal Medicine, Seoul National University Hospital, seoul, Korea, Republic of
| |
Collapse
|
13
|
Kang JY, Song SH, Yun J, Jeon MS, Kim HP, Han SW, Kim TY. Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression. Oncogene 2015; 34:5677-84. [PMID: 25703332 DOI: 10.1038/onc.2015.17] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Revised: 12/15/2014] [Accepted: 01/16/2015] [Indexed: 12/25/2022]
Abstract
The CCCTC-binding factor (CTCF)/cohesin complex regulates gene transcription via high-order chromatin organization of the genome. De novo methylation of CpG islands in the promoter region is an epigenetic hallmark of gene silencing in cancer. Although the CTCF/cohesin complex preferentially targets hypomethylated DNA, it remains unclear whether the CTCF/cohesin-mediated high-order chromatin structure is affected by DNA methylation during tumorigenesis. We found that DNA methylation downregulates the expression of prostaglandin-endoperoxide synthase 2 (PTGS2), which is an inducible, rate-limiting enzyme for prostaglandin synthesis, by disrupting CTCF/cohesin-mediated chromatin looping. We show that the CTCF/cohesin complex is enriched near a CpG island associated with PTGS2 and that the PTGS2 locus forms chromatin loops through methylation-sensitive binding of the CTCF/cohesin complex. DNA methylation abolishes the association of the CTCF/cohesin complex with the PTGS2 CpG island. Disruption of chromatin looping by DNA methylation abrogates the enrichment of transcriptional components, such as positive elongation factor b, at the transcriptional start site of the PTGS2 locus. These alterations result in the downregulation of PTGS2. Our results provide evidence that CTCF/cohesin-mediated chromatin looping of the PTGS2 locus is dynamically influenced by the DNA methylation status.
Collapse
Affiliation(s)
- J Y Kang
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S H Song
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - J Yun
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - M S Jeon
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - H P Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S W Han
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| | - T Y Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
14
|
Lim SH, Kim TW, Hong YS, Han SW, Lee KH, Kang HJ, Hwang IG, Lee JY, Kim HS, Kim ST, Lee J, Park JO, Park SH, Park YS, Lim HY, Jung SH, Kang WK. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. Br J Cancer 2015; 113:1421-6. [PMID: 26505681 PMCID: PMC4815882 DOI: 10.1038/bjc.2015.371] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Revised: 09/22/2015] [Accepted: 10/05/2015] [Indexed: 12/19/2022] Open
Abstract
Background: The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic colorectal cancer. Methods: We undertook a double-blind, placebo-controlled phase III trial of 269 patients previously treated for metastatic colorectal cancer and enrolled in 5 centres in South Korea. Patients were randomly assigned (1 : 1) to one of the following groups: FOLFIRI/XELIRI plus simvastatin (40 mg) or FOLFIRI/XELIRI plus placebo. The FOLFIRI regimen consisted of irinotecan at 180 mg m−2 as a 90-min infusion, leucovorin at 200 mg m−2 as a 2-h infusion, and a bolus injection of 5-FU 400 mg m−2 followed by a 46-h continuous infusion of 5-FU at 2400 mg m−2. The XELIRI regimen consisted of irinotecan at 250 mg m−2 as a 90-min infusion with capecitabine 1000 mg m−2 twice daily for 14 days. The primary end point was progression-free survival (PFS). Secondary end points included response rate, duration of response, overall survival (OS), time to progression, and toxicity. Results: Between April 2010 and July 2013, 269 patients were enrolled and assigned to treatment groups (134 simvastatin, 135 placebo). The median PFS was 5.9 months (95% CI, 4.5–7.3) in the XELIRI/FOLFIRI plus simvastatin group and 7.0 months (95% CI, 5.4–8.6) in the XELIRI/FOLFIRI plus placebo group (P=0.937). No significant difference was observed between the two groups with respect to OS (median, 15.9 months (simvastatin) vs 19.9 months (placebo), P=0.826). Grade ⩾3 nausea and anorexia were noted slightly more often in patients in the simvastatin arm compared with with the placebo arm (4.5% vs 0.7%, 3.0% vs 0%, respectively). Conclusions: The addition of 40 mg simvastatin to the XELIRI/FOLFIRI regimens did not improve PFS in patients with previously treated metastatic colorectal cancer nor did it increase toxicity.
Collapse
Affiliation(s)
- S H Lim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - T W Kim
- Division of Hematology-Oncology, Department of Medicine, Asan Medical Center, Seoul, South Korea
| | - Y S Hong
- Division of Hematology-Oncology, Department of Medicine, Asan Medical Center, Seoul, South Korea
| | - S-W Han
- Division of Hematology-Oncology, Department of Medicine, Seoul National University Hospital, Seoul, South Korea
| | - K-H Lee
- Division of Hematology-Oncology, Department of Medicine, Seoul National University Hospital, Seoul, South Korea
| | - H J Kang
- Division of Hematology-Oncology, Department of Medicine, Korea Cancer Center Hospital, Seoul, South Korea
| | - I G Hwang
- Division of Hematology-Oncology, Department of Medicine, Chungang University Hospital, Seoul, South Korea
| | - J Y Lee
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - H S Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - S T Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - J Lee
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - J O Park
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - S H Park
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Y S Park
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - H Y Lim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - S-H Jung
- Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.,Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - W K Kang
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| |
Collapse
|
15
|
Park HJ, Kim K, Paik JH, Chie EK, Kim S, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy? Clin Transl Oncol 2015; 18:625-31. [PMID: 26459257 DOI: 10.1007/s12094-015-1409-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 09/07/2015] [Indexed: 12/28/2022]
Abstract
PURPOSE To analyze the expression of c-Met, and to investigate correlations between the expression of c-Met, clinicopathologic variables, and survival in patients undergoing curative surgery followed by adjuvant chemoradiotherapy for extrahepatic bile duct (EHBD) cancer. METHODS Ninety EHBD cancer patients who underwent curative resection followed by adjuvant chemoradiotherapy were enrolled. Expression of c-Met was assessed with immunohistochemical staining on tissue microarray. The correlation between clinicopathologic variables and survival outcomes was evaluated using Kaplan-Meier method and Cox proportional hazard model. RESULTS On univariate analysis, 66 patients (76.7 %) showed c-Met expression. c-Met expression had a significant impact on 5-year overall survival (OS) (43.0 % in c-Met(+) vs. 25.0 % in c-Met(-), p = 0.0324), but not on loco-regional relapse-free survival or distant metastasis-free survival (DMFS). However, on multivariate analysis incorporating tumor location and nodal involvement, survival difference was not maintained (p = 0.2940). Tumor location was the only independent prognostic factor predicting OS (p = 0.0089). Hilar location tumors, nodal involvement, and poorly differentiated tumors were all identified as independent prognostic factors predicting inferior DMFS (p = 0.0030, 0.0013, and 0.0037, respectively). CONCLUSIONS This study showed that c-Met expression was not associated with survival outcomes in EHBD cancer patients undergoing curative resection followed by adjuvant chemoradiotherapy. Further studies are needed to fully elucidate the prognostic value of c-Met expression in these patients.
Collapse
Affiliation(s)
- H J Park
- Department of Radiation Oncology, Hanyang University Hospital, Seoul, Republic of Korea
| | - K Kim
- Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea.
| | - J H Paik
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - E K Chie
- Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea
- Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea
| | - S Kim
- Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea
| | - J-Y Jang
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S W Kim
- Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S-W Han
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D-Y Oh
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S-A Im
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - T-Y Kim
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y-J Bang
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S W Ha
- Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea
- Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea
| |
Collapse
|
16
|
Jin Z, Park C, Song KJ, Kang S, Ko KE, Park C, Ko RK, Han SW. Micro-Structural Properties of YBa2Cu3O(7-x)/ZnO Nanorods on SrTiO3. J Nanosci Nanotechnol 2015; 15:642-646. [PMID: 26328417 DOI: 10.1166/jnn.2015.8326] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
We examined the local structural and the interfacial properties of YBa2Cu3O(7-x) (YBCO)/ZnO nanorods on SrTiO3 (STO) substrates using various measurements. Vertically aligned ZnO nanorods were synthesized on STO substrates using a catalyst-free metal-organic chemical vapor deposition. YBCO films were deposited ex-situ on the ZnO nanorods/STO templates using a DC magnetron sputtering deposition. X-ray diffraction revealed that the YBCO films were crystallized along their c-axes on the ZnO nanorods/STO templates. Transmission electron microscopy measurements demonstrated that YBCO filled the space between ZnO nanorods and that both interfaces of YBCO/ZnO nanorods and ZnO nanorods/STO were quite clean with no disorder. Polarization-dependent extended X-ray absorption fine structure measurements at the Cu K edge showed extra disorder in the CuO2 planes of YBCO/ZnO nanorods/STO, compared with that of YBCO/STO. The superconductivity transition temperature (T(c)) of YBCO/ZnO nanorods/STO was approximately 50 K whereas that of YBCO/STO was 93 K. The decrease of T(c) of YBCO/ZnO nanorods/STO was ascribed to the structural disorder of CuO2 planes as well as grain boundaries in the YBCO films.
Collapse
|
17
|
Min A, Im SA, Kim S, Song SH, Lee KH, Han SW, Oh DY, Kim TY, Bang YJ. Abstract P4-16-06: Histone deacetylases inhibitor SAHA enhances anti-tumor effects of poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in breast cancer cells. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-16-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, has been found to have a therapeutic potential for treating cancers that have an impaired DNA repair ability. However, some cancer presents acquired resistance to PARP inhibitor or platinum. Histone deacetylases (HDACs) are important to enable functional homologous recombination (HR) by regulating the expression of HR-related genes and promoting the accurate assembly of HR-directed subnuclear foci. Thus, HDAC inhibitors have emerged recently as a class of therapeutic agents for the treatment of cancer by inhibiting DNA repair. For this mechanism, HDAC inhibition would enhance the anti-tumor effect of PARP inhibitor in cancer cells by blocking DNA repair pathway.
Materials and Methods: We determined whether SAHA, a HDAC inhibitor could enhance the growth inhibition of olaparib on breast cancer cell lines using MTT assay. We examined whether exposure to SAHA affects the expression level of genes involved in HR. The accumulation of DNA double strand breaks (DSBs) induced by combination treatment was accessed by the comet assay. Cell cycle analysis and molecular changes induced by combination of olaparib plus SAHA were also performed. These in vitro data were validated in the in vivo xenograft model as well.
Results: Triple-negative breast cancer cell lines showed heterogeneous response to dual inhibition of PARP and HDACs. SAHA enhanced olaparib-induced cell death of MDA-MB-157 and HCC1143 but not of HCC70 and MDA-MB-468. Combination of olaparib plus SAHA caused a greater decrease of pAKT, pERK, and pSTAT3 in MDA-MB-157 and HCC1143 cells compared with monotherapy either olaparib or SAHA. Furthermore, inhibition of PARP increased the accumulation of DNA DSBs induced by SAHA in these two cell lines, MDA-MB-157 and HCC1143. There was no change in proliferative pathway activation in HCC70 and MDA-MB-468 cells with combination of olaparib plus SAHA. Our findings showed that triple-negative breast cancer cells are differentially effective to combination of SAHA plus olaparib which increased levels of unrepaired DNA DSBs.
Conclusion: HDAC inhibitor SAHA enhances growth inhibitory activity of PARP inhibitor olaparib in several triple-negative breast cancer cells with increased accumulation of DNA DSBs. Our results provide a rationale for the future clinical trials of olaparib combined with SAHA in the treatment of cancers that have an impaired DNA repair ability.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-16-06.
Collapse
Affiliation(s)
- A Min
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| | - S-A Im
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| | - S Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| | - S-H Song
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| | - K-H Lee
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| | - S-W Han
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| | - D-Y Oh
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| | - T-Y Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| | - Y-J Bang
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
18
|
Kim HP, Cho GA, Han SW, Shin JY, Jeong EG, Song SH, Lee WC, Lee KH, Bang D, Seo JS, Kim JI, Kim TY. Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis. Oncogene 2013; 33:5434-41. [PMID: 24240688 DOI: 10.1038/onc.2013.490] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2013] [Revised: 10/01/2013] [Accepted: 10/04/2013] [Indexed: 12/20/2022]
Abstract
Gene fusion is involved in the development of various types of malignancies. Recent advances in sequencing technology have facilitated identification of gene fusions and have stimulated the research of this field in cancer. In the present study, we performed next-generation transcriptome sequencing in order to discover novel gene fusions in gastric cancer. A total of 282 fusion transcript candidates were detected from 12 gastric cancer cell lines by bioinformatic filtering. Among the candidates, we have validated 19 fusion transcripts, which are 7 inter-chromosomal and 12 intra-chromosomal fusions. A novel DUS4L-BCAP29 fusion transcript was found in 2 out of 12 cell lines and 10 out of 13 gastric cancer tissues. Knockdown of DUS4L-BCAP29 transcript using siRNA inhibited cell proliferation. Soft agar assay further confirmed that this novel fusion transcript has tumorigenic potential. We also identified that microRNA-coding gene PVT1, which is amplified in double minute chromosomes in SNU-16 cells, is recurrently involved in gene fusion. PVT1 produced six different fusion transcripts involving four different genes as fusion partners. Our findings provide better insight into transcriptional and genetic alterations of gastric cancer: namely, the tumorigenic effects of transcriptional read-through and a candidate region for genetic instability.
Collapse
Affiliation(s)
- H-P Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - G-A Cho
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - S-W Han
- 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea [2] Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - J-Y Shin
- 1] Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea [2] Psoma Therapeutic Inc, Seoul, Korea
| | - E-G Jeong
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - S-H Song
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - W-C Lee
- 1] Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea [2] Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea
| | - K-H Lee
- 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea [2] Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - D Bang
- Department of Chemistry, College of Science, Yonsei University, Seoul, Korea
| | - J-S Seo
- 1] Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea [2] Psoma Therapeutic Inc, Seoul, Korea [3] Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea [4] Department of Biochemistry, Seoul National University College of Medicine, Seoul, Korea [5] Macrogen Inc., Seoul, Korea
| | - J-Il Kim
- 1] Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea [2] Psoma Therapeutic Inc, Seoul, Korea [3] Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea [4] Department of Biochemistry, Seoul National University College of Medicine, Seoul, Korea
| | - T-Y Kim
- 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea [2] Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea [3] Department of Molecular Medicine & Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
19
|
Choi SW, Kim MK, Han SW, Han SH, Lee BK, Lee SU, Hur SH, Lim SW, Moon KW, Lee SG, Lee SH, Oh SK, Chea JG, Joo SJ, Jo MC, Hong KS, Ryu KH. Apparent treatment-resistant hypertension among elderly Korean hypertensives: an insight from the HIT registry. J Hum Hypertens 2013; 28:201-5. [PMID: 23985877 DOI: 10.1038/jhh.2013.76] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2013] [Revised: 07/09/2013] [Accepted: 07/10/2013] [Indexed: 11/09/2022]
Abstract
The aim of this study was to determine the clinical characteristics of patients with resistant hypertension (RH) and predictors among elderly Korean hypertensives. This prospective, multi-center, observational study evaluated 2439 elderly hypertensive patients between December 2008 and November 2011, who visited secondary hypertension clinics for high blood pressure (BP). Patients were categorized as resistant if their BP was ≥140/90 mm Hg and if they reported using antihypertensive medications from three different drug classes, including a diuretic or drugs from ≥4 antihypertensive drug classes, regardless of BP. Characteristics of patients with RH were compared with those of patients who were controlled with one or two antihypertensive medications after 6-month antihypertensive treatment. In comparison with 837 patients with non-RH, 404 patients with RH were more likely to be aware of their status of high BP before enrollment and have a high baseline systolic BP ≥160 mm Hg, microalbuminuria, high body mass index (BMI) ≥24 kg m(-2) and diabetes mellitus (DM). In drug-naive patients, awareness of hypertension at baseline was the only independent predictor for RH. In elderly Korean hypertensives, BMI (≥24 kg m(-2)), baseline systolic BP (≥160 mm Hg), microalbuminuria, DM and awareness of hypertension showed an association with RH.
Collapse
Affiliation(s)
- S-W Choi
- Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea
| | - M-K Kim
- Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea
| | - S W Han
- Department of Internal Medicine, Hangang Sacred Heart Hospital, Hallym University, Seoul, Korea
| | - S H Han
- Division of Cardiology, Gachon University Gil Hospital, Incheon, Korea
| | - B K Lee
- Division of Cardiology, Gangnam Severance Hospital, Yonsei University, Seoul, Korea
| | - S U Lee
- Department of Internal Medicine, Gwangju Christian Hospital, Gwangju, Korea
| | - S-H Hur
- Division of Cardiology, Daejeon St. Mary's Hospital, The Catholic University of Korea, Daejeon, Korea
| | - S W Lim
- Division of Cardiology, Bundang Cha Hospital, Cha University, Seongnam, Korea
| | - K W Moon
- Division of Cardiology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea
| | - S G Lee
- Division of Cardiology, Ulsan University Hospital, Ulsan, Korea
| | - S H Lee
- Department of Internal Medicine, Dongkang Medical Center, Ulsan, Korea
| | - S K Oh
- Division of Cardiology, Wonkwang University School of Medicine and Hospital, Iksan, Korea
| | - J G Chea
- Division of Cardiology, Chonbuk National University Hospital, Jeonju, Korea
| | - S J Joo
- Division of Cardiology, Jeju National University Hospital, Jeju, Korea
| | - M C Jo
- Division of Cardiology, Chungbuk National University Hospital, Cheongju, Korea
| | - K-S Hong
- Division of Cardiology, Chooncheon Sacred Heart Hospital, Hallym University, Chooncheon, Korea
| | - K-H Ryu
- Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea
| | | |
Collapse
|
20
|
Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene 2013; 33:3334-41. [PMID: 23873022 DOI: 10.1038/onc.2013.285] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2012] [Revised: 05/26/2013] [Accepted: 05/28/2013] [Indexed: 12/17/2022]
Abstract
Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. As with other molecularly targeted agents, the emergence of acquired resistance to HER2-directed treatment is an imminent therapeutic problem for HER2-positive gastric cancer. In order to investigate the mechanisms of acquired resistance to HER2-directed treatment in gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (SNU216 LR) in vitro by chronic exposure of a HER2-positive gastric cancer cell line (SNU216) to lapatinib. The resultant SNU216 LR cells were also resistant to gefitinib, cetuximab, trastuzumab, afatinib and dacomitinib. Interestingly, SNU216 LR cells displayed an epithelial-mesenchymal transition (EMT) phenotype and maintained the activation of MET, HER3, Stat3, Akt and mitogen-activated protein kinase signaling in the presence of lapatinib. Using gene expression arrays, we identified the upregulation of a variety of EMT-related genes and extracellular matrix molecules, such as Testican-1, in SNU216 LR cells. We showed that the inhibition of Testican-1 by small interfering RNA decreased Testican-1-induced, MET-dependent, downstream signaling, and restored sensitivity to lapatinib in these cells. Furthermore, treatment with XAV939 selectively inhibited β-catenin-mediated transcription and Testican-1-induced EMT signaling, leading to G1 arrest. Taken together, these data support the potential role of EMT in acquired resistance to HER2-directed treatment in HER2-positive gastric cancer, and provide insights into strategies for preventing and/or overcoming this resistance in patients.
Collapse
Affiliation(s)
- H-P Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S-W Han
- 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea [2] Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S-H Song
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - E-G Jeong
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - M-Y Lee
- School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology(POSTECH), Pohang, Republic of Korea
| | - D Hwang
- School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology(POSTECH), Pohang, Republic of Korea
| | - S-A Im
- 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea [2] Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y-J Bang
- 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea [2] Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - T-Y Kim
- 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea [2] Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea [3] WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
21
|
Seo SY, Jeong ES, Kwak CH, Park CI, Jin Z, Kim SH, Han SW. X-ray absorption fine structure study of cobalt ion distribution in ferromagnetic Zn(1-x)Co(x)O films. J Phys Condens Matter 2013; 25:256005. [PMID: 23733006 DOI: 10.1088/0953-8984/25/25/256005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
We examined the distribution of Co ions in ferromagnetic n-type Zn(1-x)Co(x)O semiconducting films with Co concentrations of 0.0-0.07 using x-ray absorption fine structure (XAFS) measurements at the Co and Zn K edges. Extended XAFS (EXAFS) revealed that Co ions mainly occupied the zinc sites in the films. X-ray absorption near edge structure (XANES) spectra demonstrated that the pre-edge peak of the Co K edge was substantially affected by the second neighboring Co ions in the zinc sites due to their environmental potential distortion. From the pre-edge peak and EXAFS analysis using ab initio calculations, we found that Co ions uniformly occupied the zinc sites of the Zn0.93Co0.07O film, whereas the Co ions of the Zn0.97Co0.03O and Zn0.95Co0.05O films were substituted at the zinc sites with a non-uniform distribution. The ferromagnetic properties of the Zn0.93Co0.07O film may be induced by direct interaction between the magnetic dipoles of the Co ions with a mean distance of 4.3 Å, or by the Co conduction-electron mediation.
Collapse
Affiliation(s)
- S-Y Seo
- Department of Materials Science and Engineering, Pohang University of Science and Technology, Pohang 790-784, Korea
| | | | | | | | | | | | | |
Collapse
|
22
|
Park JH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kang GH, Chie EK, Ha SW, Jeong SY, Park KJ, Park JG, Kim TY. The beneficial effect of palliative resection in metastatic colorectal cancer. Br J Cancer 2013; 108:1425-31. [PMID: 23481187 PMCID: PMC3629435 DOI: 10.1038/bjc.2013.94] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background: We aimed to determine the role of palliative resection in metastatic colorectal cancer (mCRC) and ascertain which patient populations would benefit most from this treatment. Methods: A total of 1015 patients diagnosed with mCRC at Seoul National University Hospital between 2000 and 2009 were retrospectively studied. Results: Of the 1015 patients, 168 patients with only liver and/or lung metastasis received curative resection. The remaining 847 patients were treated with palliative chemotherapy and/or palliative resection combined with best supportive care. Palliative resection was performed in 527 (62.2%) cases (complete resection with negative margin (R0) in 93, R1/2 in 434). Resected patients had a more prolonged median overall survival (OS) than unresected patients (21.3 vs 14.1 months; P<0.001). In multivariate analysis, R0 resection was found to be associated with a superior OS compared with R1/2 resection (51.3 vs 19.1 months; P<0.001) and no resection (51.3 vs 14.1 months; P<0.001). When we performed propensity score matching, palliative resection was found to be related to prolonged OS (hazard ratio=0.72, 95% confidence interval=0.59–0.89; P=0.003). Conclusion: Palliative resection without residual disease and chemotherapy confers a longer-term survival outcome than palliative chemotherapy alone in mCRC patient subset.
Collapse
Affiliation(s)
- J H Park
- Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul 110-744, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Jeong ES, Park C, Jin Z, Yoo J, Yi GC, Han SW. Orientation-dependent local structural properties of Zn(1-x)Mg(x)O nanorods studied by extended X-ray absorption fine structure. J Nanosci Nanotechnol 2013; 13:1880-1883. [PMID: 23755611 DOI: 10.1166/jnn.2013.6966] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The orientation-dependent structural properties of Zn(1-x)Mg(x)O nanorods with different Mg concentrations were investigated quantitatively using polarization-dependent extended X-ray absorption fine structure (EXAFS) measurements at the Zn K edge. Vertically-aligned Zn(1-x)Mg(x)O nanorods were synthesized on Si substrates using catalyst free metal organic chemical vapor deposition. Polarization-dependent EXAFS measurements showed that Mg ions mainly occupied the Zn sites of the nanorods. EXAFS revealed that the distance between Zn-Mg pairs in all directions is - 0.2 angstroms shorter than that of Zn-Zn pairs and that there is a substantial amount of disorder in the Mg sites of the nanorods, independent of Mg concentrations.
Collapse
Affiliation(s)
- E S Jeong
- Department of Physics Education, Institute of Fusion Science, Chonbuk National University, Jeonju 561-756, Korea
| | | | | | | | | | | |
Collapse
|
24
|
Im SA, Oh DY, Keam B, Lee KS, Ahn JH, Sohn J, Ahn JS, Kim JH, Lee MH, Lee KE, Kim HJ, Lee KH, Han SW, Kim SY, Kim SB, Im YH, Ro J, Park HS. Abstract PD09-05: Single nucleotide polymorphism of XRCC1 which participates in DNA repair mechanism predicts clinical outcome in relapsed or metastatic breast cancer patients treated with S1 and oxaliplatin chemotherapy: Results from multicenter prospective study (TORCH_KCSG BR07-03). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd09-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: S1 and oxaliplatin (SOX) combination chemotherapy is an effective regimen in anthracycline and taxane pretreated metastatic breast cancer (MBC) patients with manageable toxicities (KCSG BR07-03, SABCS 2011 #Abst P3-16-06). The aim of this study was to investigate the association of the single nucleotide polymorphisms (SNPs) and clinical outcome in MBC treated with SOX chemotherapy.
Patients and Methods: A total of 87 MBC patients previously treated with or resistant to anthracycline and taxane chemotherapy were enrolled in this prospective multicenter trial. The patients received S-1 80mg/m2/day (day 1–14) and oxaliplatin 130 mg/m2 (day 1) every 3 weeks till progression. Among the 87 patients, 77 patients were available for SNP analysis. Germline DNA from peripheral blood (PB) mononuclear cells was extracted. SNPs in 4 genes from pathways that may influence cellular sensitivity to S1 and oxaliplatin (TS, ERCC, XPD, and XRCC) were genotyped from PB sample using PCR-restriction fragment length polymorphism.
Results: Overall response rate (RR) was 38.5% (95% CI: 27.7–49.3) and disease control rate was 67.9% (95% CI:57.5–78.3) to SOX. Median time-to-progression (TTP) and overall survival (OS) were 6.0 mo (95% CI: 5.1–6.9 mo) and 19.4 mo (95% CI: not estimated), respectively. XRCC1 Arg194Trp SNP which participates in DNA repair mechanism showed correlation with the clinical outcome. RR was tend to higher in XRCC1 Arg194Trp CC genotype compared with CT or TT genotype (50.0 % vs 35.1% or 12.5%, P = 0.121). TTP of patients with CC genotype in XRCC1 Arg194Trp was significantly longer than the TTP of patients with CT or TT genotype (median TTP: 6.4 mo in CC, 5.9 mo in CT, 3.0 mo in TT, P = 0.007) as well as overall survival (OS) (median OS: not reached in CC, 13.9 mo in CT, 7.1 mo in TT, P = 0.006). After adjusting for hormone receptor status, performance status, and visceral involvement, prognostic value of XRCC1 Arg194Trp SNP remained significant (Hazard Ratio=1.322 and 4.484, P = 0.016). Other SNPs were not significantly associated with survival or toxicities.
Conclusion: XRCC1 Arg194Trp SNP is associated with clinical outcome of MBC patients treated with SOX chemotherapy. Further studies of the relationship between germline polymorphisms in XRCC1 and functional mechanism researches are warranted.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD09-05.
Collapse
Affiliation(s)
- S-A Im
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - D-Y Oh
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - B Keam
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - KS Lee
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - J-H Ahn
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - J Sohn
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - JS Ahn
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - JH Kim
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - MH Lee
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - KE Lee
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - HJ Kim
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - K-H Lee
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - SW Han
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - S-Y Kim
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - SB Kim
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - Y-H Im
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - J Ro
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - H-S Park
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| |
Collapse
|
25
|
Pereira Lopes FR, Martin PKM, Frattini F, Biancalana A, Almeida FM, Tomaz MA, Melo PA, Borojevic R, Han SW, Martinez AMB. Double gene therapy with granulocyte colony-stimulating factor and vascular endothelial growth factor acts synergistically to improve nerve regeneration and functional outcome after sciatic nerve injury in mice. Neuroscience 2012; 230:184-97. [PMID: 23103791 DOI: 10.1016/j.neuroscience.2012.10.025] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2012] [Revised: 10/09/2012] [Accepted: 10/10/2012] [Indexed: 12/17/2022]
Abstract
Peripheral-nerve injuries are a common clinical problem and often result in long-term functional deficits. Reconstruction of peripheral-nerve defects is currently undertaken with nerve autografts. However, there is a limited availability of nerves that can be sacrificed and the functional recovery is never 100% satisfactory. We have previously shown that gene therapy with vascular endothelial growth factor (VEGF) significantly improved nerve regeneration, neuronal survival, and muscle activity. Our hypothesis is that granulocyte colony-stimulating factor (G-CSF) synergizes with VEGF to improve the functional outcome after sciatic nerve transection. The left sciatic nerves and the adjacent muscle groups of adult mice were exposed, and 50 or 100 μg (in 50 μl PBS) of VEGF and/or G-CSF genes was injected locally, just below the sciatic nerve, and transferred by electroporation. The sciatic nerves were transected and placed in an empty polycaprolactone (PCL) nerve guide, leaving a 3-mm gap to challenge nerve regeneration. After 6 weeks, the mice were perfused and the sciatic nerve, the dorsal root ganglion (DRG), the spinal cord and the gastrocnemius muscle were processed for light and transmission electron microscopy. Treated animals showed significant improvement in functional and histological analyses compared with the control group. However, the best results were obtained with the G-CSF+VEGF-treated animals: quantitative analysis of regenerated nerves showed a significant increase in the number of myelinated fibers and blood vessels, and the number of neurons in the DRG and motoneurons in the spinal cord was significantly higher. Motor function also showed that functional recovery occurred earlier in animals receiving G-CSF+VEGF-treatment. The gastrocnemius muscle showed an increase in weight and in the levels of creatine phosphokinase, suggesting an improvement of reinnervation and muscle activity. These results suggest that these two factors acted synergistically and optimized the nerve repair potential, improving regeneration after a transection lesion.
Collapse
Affiliation(s)
- F R Pereira Lopes
- Programa de Neurociência Básica e Clínica, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, RJ, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Han SW, Sa KH, Kim SI, Lee SI, Park YW, Lee SS, Yoo WH, Soe JS, Nam EJ, Lee J, Park JY, Kang YM. CCR5 gene polymorphism is a genetic risk factor for radiographic severity of rheumatoid arthritis. ACTA ACUST UNITED AC 2012; 80:416-23. [PMID: 22924548 DOI: 10.1111/j.1399-0039.2012.01955.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2012] [Revised: 07/11/2012] [Accepted: 08/06/2012] [Indexed: 11/29/2022]
Abstract
The chemokine receptor [C-C chemokine receptor 5 (CCR5)] is expressed on diverse immune effecter cells and has been implicated in the pathogenesis of rheumatoid arthritis (RA). This study sought to determine whether single-nucleotide polymorphisms (SNPs) in the CCR5 gene and their haplotypes were associated with susceptibility to and severity of RA. Three hundred fifty-seven patients with RA and 383 healthy unrelated controls were recruited. Using a pyrosequencing assay, we examined four polymorphisms -1118 CTAT(ins) (/del) (rs10577983), 303 A>G (rs1799987), 927 C>T (rs1800024), and 4838 G>T (rs1800874) of the CCR5 gene, which were distributed over the promoter region as well as the 5' and 3' untranslated regions. No significant difference in the genotype, allele, and haplotype frequencies of the four selected SNPs was observed between RA patients and controls. CCR5 polymorphisms of -1118 CTAT(del) (P = 0.012; corrected P = 0.048) and 303 A>G (P = 0.012; corrected P = 0.048) showed a significant association with radiographic severity in a recessive model, and, as a result of multivariate logistic regression analysis, were found to be an independent predictor of radiographic severity. When we separated the erosion score from the total Sharp score, the statistical significance of CCR5 polymorphisms showed an increase; -1118 CTAT(ins) (/del) (P = 0.007; corrected P = 0.028) and 303 A>G (P = 0.007; corrected P = 0.028). Neither SNPs nor haplotypes of the CCR5 gene showed a significant association with joint space narrowing score. These results indicate that genetic polymorphisms of CCR5 are an independent risk factor for radiographic severity denoted by modified Sharp score, particularly joint erosion in RA.
Collapse
Affiliation(s)
- S W Han
- Department of Internal Medicine, Daegu Fatima hospital, Daegu, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Postoperative chemoradiotherapy for gallbladder cancer. Strahlenther Onkol 2012; 188:388-92. [PMID: 22402869 DOI: 10.1007/s00066-012-0074-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2011] [Accepted: 01/11/2012] [Indexed: 10/28/2022]
Abstract
PURPOSE The goal of this work was to analyze the outcome of adjuvant chemoradiotherapy for patients with gallbladder cancer who underwent surgical resection and to identify the prognostic factors for these patients. PATIENTS AND METHODS Between August 1989 and November 2006, 47 patients with gallbladder cancer underwent surgical resection followed by adjuvant radiotherapy. There were 21 males and 26 females, and median age was 60 years (range 44-75 years). Postoperative radiotherapy was delivered to the tumor bed and regional lymph nodes up to 40-50 Gy at 2 Gy/fraction; 41 patients also received intravenous 5-fluorouracil as a radiosensitizer. Median follow-up duration was 48 months for survivors. RESULTS There were 2 isolated locoregional recurrences, 14 isolated distant metastases, and 7 combined locoregional and distant relapses. The 5-year overall survival rate was 43.7%. According to the extent of resection, the 5-year overall survival rates were 52.8%, 20.0%, and 0% in R0-, R1-, and R2-resected patients, respectively (p = 0.0038). On multivariate analysis incorporating extent of resection, T stage, N stage, performance of lymph node dissection, and histologic differentiation, extent of resection was the only prognostic factor associated with overall survival (p = 0.0075). Among the 37 patients with R0 resection, there was no difference of 5-year overall survival rates in patients with N0, N1, and Nx diseases (46.2%, 60.0%, and 44.4%, respectively, p = 0.6246). As for significant treatment-related morbidity, there was only 1 patient with grade 4 gastric ulcer. CONCLUSION Adjuvant chemoradiotherapy after R0 resection can achieve a good long-term survival rate in gallbladder cancer patients, even in those with lymph node metastases, and may play a role for patients who underwent R0 resection of primary tumor without lymph node dissection.
Collapse
Affiliation(s)
- K Kim
- Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 110-744, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Im SA, Oh DY, Lee KS, Ahn JH, Shon J, Ahn JS, Kim JH, Han SW, Lee MH, Lee KE, Lee K, Kim HJ, Keam B, Kim SY, Kim SB, Im YH, Ro J, Park HS. P3-16-06: Phase II Trial of TS-1 in Combination with Oxaliplatin (SOX) in Patients with Metastatic Breast Cancer (MBC) Previously Treated with Anthracycline and Taxane Chemotherapy [TORCH] [Korean Cancer Study Group (KCSG) BR07-03]. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-16-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Oxaliplatin, a platinum analogue, is an active drug in advanced anthracycline and taxane-pretreated breast cancer patients as a single agent and with 5-fluorouracil (5-FU) combination. TS-1 was developed by the scientific theory of both potentiating antitumor activity of 5-FU and reducing gastrointestinal toxicity. This trial was performed to evaluate the efficacy and safety of TS-1 in combination with oxaliplatin in metastatic breast cancer (MBC) patients previously treated with anthracycline and taxane chemotherapy.
Methods: Between October 2007 and October 2009, MBC patients were enrolled in this prospective multicenter trial. Eligible criteria included age ≥18 years, at least one measurable lesion, prior treatment with anthracycline and taxane chemotherapy, and ECOG Performance Status 0–2. TS-1 40 mg/m2 b.i.d. on days 1–14 with oxaliplatin 130 mg/m2 on day 1 were administered every 3 weeks till disease progression. Primary end-point was response rate, and secondary end-points were time-to-progression (TTP), overall survival (OS), duration of response (DOR) and toxicities. Response was evaluated every 6 weeks according to the RECIST criteria v. 1.0 and toxicity was assessed with NCICTCAE v.3.0.(ClinicalTrials.gov identifier NCT00527930).
Results: A total of 87 patients were enrolled. Median age was 48 years (range 30–71 years). Nineteen patients (21.8%) had de novo stage IV and 68 patients (78.2%) had recurrent disease. Thirty-five patients (40.2%) received two-lines of prior chemotherapy in palliative setting. Forty-eight patients (55.2%) had ≥ 3 disease sites. Fifty-four patients (62.1%) were hormone receptor positive, and 25 patients (28.7%) were triple negative. Five patients received prior anti-HER2 therapy. A total of 525 cycles were administered (median 6 cycles, range: 1 ∼ 22+ cycle). In per-protocol analysis, overall response rate was 38.5% (95% CI: 27.7−49.3) (CR 0%, PR 38.5%) and disease control rate (CR, PR, and SD) was 67.9% (95% CI: 57.5−78.3). Median TTP, OS, and DOR were 6.0 months (95% CI: 5.1−6.9 months), 19.4 months (95% CI: not estimated), 6.6 months (95% CI: 3.7−9.6 months), respectively. RR was not different by triple negativity (39.1% in TNBC vs. 38.2% in non-TNBC, P=0.361). TTP was not different according to the number of prior chemotherapy regimens. Reported grade 3 or 4 toxicities (per cycle) were neutropenia (10.3%), thrombocytopenia (5.5%), diarrhea (1.9%), vomiting (1.9%), and stomatitis (0.2%). There was no treatment-related death.
Conclusions: SOX is an effective regimen in anthracycline and taxane pretreated MBC patients with manageable toxicities.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-16-06.
Collapse
Affiliation(s)
- S-A Im
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - D-Y Oh
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - KS Lee
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - J-H Ahn
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - J Shon
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - JS Ahn
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - JH Kim
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - SW Han
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - MH Lee
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - KE Lee
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - K Lee
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - HJ Kim
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - B Keam
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - S-Y Kim
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - SB Kim
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - YH Im
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - J Ro
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - H-S Park
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| |
Collapse
|
29
|
Kim SH, Chang Y, Kim JH, Song HJ, Seo J, Kim SH, Han SW, Nam EJ, Choi TY, Lee SJ, Kim SK. Insular cortex is a trait marker for pain processing in fibromyalgia syndrome--blood oxygenation level-dependent functional magnetic resonance imaging study in Korea. Clin Exp Rheumatol 2011; 29:S19-S27. [PMID: 21813055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2010] [Accepted: 03/08/2011] [Indexed: 05/31/2023]
Abstract
OBJECTIVES To investigate the variability in cerebral activation according to pain intensity and the association between variability in cerebral activation and clinical features in patients with fibromyalgia syndrome (FMS) using functional magnetic resonance imaging (fMRI). METHODS Nineteen FMS female patients and 22 age-matched healthy female controls were enrolled in this study. Changes in cerebral activation area were measured using blood oxygenation level-dependent (BOLD) contrast fMRI after application of both medium and high pressure stimuli to the left thumbnail bed. RESULTS We identified the insular cortex (IC) and superior temporal gyrus (STG) as regions of interest (ROIs) in this analysis. Cerebral activation at the bilateral IC in response to high pressure stimuli was significantly greater in FMS patients than it was in the controls, whereas there were no differences in BOLD signal changes in the STG regions between FMS patients and controls, irrespective of pain level. Prominent signal changes at both ROIs in FMS patients were noted between high and medium pressure (p<0.001 contralateral IC, p=0.001 for ipsilateral IC, p=0.008 for contralateral STG, and p=0.049 for ipsilateral STG). BOLD signal changes on the contralateral STG after medium stimuli were correlated with tender point count (r=0.586, p=0.013). CONCLUSIONS This study revealed more distinct signal variability in the ICs in FMS patients than in those of controls in response to high pressure stimuli. The IC can therefore be considered to be a region susceptible to pain perception in FMS patients.
Collapse
Affiliation(s)
- S-H Kim
- Division of Rheumatology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Kwak CH, Lee YB, Seo SY, Kim SH, Park CI, Kim BH, Jin Z, Han SW. Structural, optical and electrical properties of nitrogen ion implanted ZnO nanorods. J Nanosci Nanotechnol 2011; 11:7420-7423. [PMID: 22103210 DOI: 10.1166/jnn.2011.4835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
This study examined the micro-structural and electrical properties of N+-ion-implanted ZnO nanorods. Nitrogen ions with energies of 10-90 keV and beam fluxes of 10(13)-10(16) ions/cm2 were implanted on vertically-aligned ZnO nanorods. Energy dispersive X-ray spectroscopy measurements showed that N+ ions were spread uniformly over the nanorods. Extended X-ray absorption fine structure measurements revealed that the implanted N+s had partially substituted for the oxygen sites. Photoluminescence measurements showed a neutral-donor bound exciton peak at 3.36 eV and a two-electron-satellite peak at 3.33 eV independent of the ion energy and flux. The I-V characteristic curves showed that the current density was not changed by the N+ ion energy and flux much. These results strongly suggested that the N ions substituted for the oxygen sites were neutral.
Collapse
Affiliation(s)
- C-H Kwak
- Department of Materials Science and Engineering, Pohang University of Science and Technology, Pohang 790-784, Korea
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Jeong ES, Park J, Park JG, Adipranoto DS, Kamiyama T, Han SW. Local structural properties of CuI at low temperatures. J Phys Condens Matter 2011; 23:175402. [PMID: 21493974 DOI: 10.1088/0953-8984/23/17/175402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
This study examined the local structural properties of CuI at low temperatures of 10-300 K by x-ray diffraction (XRD) and extended x-ray absorption fine structure (EXAFS) measurements at the Cu K edge. The XRD data were refined using two models, split (distorted zinc-blende structure) and non-split (zinc-blende structure), using a conventional Rietveld refinement combined with a maximum entropy method (MEM). MEM/Rietveld analyses showed that both the split and non-split models could fit the data. EXAFS revealed the split model fit to be better than the non-split model. The split distance of Cu-I pairs was approximately 0.03 Å at 15 K and increased to 0.07 Å at 300 K. XRD and EXAFS combined together suggested that the CuI crystal was in a metastable state with a distorted zinc-blende structure at low temperatures.
Collapse
Affiliation(s)
- E-S Jeong
- Division of Science Education, Institute of Fusion Sciences, Institute of Science Education, Chonbuk National University, Jeonju 561-756, Korea
| | | | | | | | | | | |
Collapse
|
32
|
Abstract
Lung carcinoma is the leading cause of carcinoma death in the world. Despite recent advances in understanding the molecular biology of lung cancer and the introduction of new therapeutic agents for its treatment, its dismal 5-year survival rate has not changed substantially. Clinical approaches have not significantly improved the survival of patients with advanced lung cancer. However, recent discoveries about the molecular mechanisms responsible for lung cancer initiation and proliferation have unveiled new targets for therapy. One of the hallmark features of cancer cells is their ability to evade programmed cell death or apoptosis. Alterations in pro- and anti-apoptotic pathways are common in cancer cells and defects in regulation of apoptosis have been implicated in both lung tumorigenesis and drug resistance. Thus, targeting apoptosis through the direct or indirect manipulation of the pro-apoptotic machinery offers a novel strategy for treatment. This mini review summaries the molecular events that contribute to drug-induced apoptosis and how lung tumors evade apoptotic death followed by an analysis of the implications for treatment.
Collapse
Affiliation(s)
- S W Han
- Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Louisville School of Medicine, Louisville, KY 40202, USA.
| | | |
Collapse
|
33
|
Lee HJ, Kim JH, Im SA, Kim DY, Keam B, Lee JH, Kim YJ, Han SW, Oh DY, Jeong SH, Yoon JH, Kim TY, Bang YJ. Abstract P5-15-01: Lamivudine Prophylaxis during Adjuvant Chemotherapy in Breast Cancer Patients with Hepatitis B Surface Antigen. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-15-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Reactivation of hepatitis B virus (HBV) in inactive hepatitis B surface antigen (HBsAg) carriers receiving cytotoxic chemotherapy is a well known complications resulting in hepatic dysfunction. Lamivudine has been reported to have a role in controlling HBV reactivation during chemotherapy. Our study aimed to report the role of lamivudine prophylaxis in breast cancer patients undergoing adjuvant chemotherapy. Methods: We retrospectively reviewed medical records of 3530 patients with stage 1-3 breast cancer who received neoadjuvant and/or adjuvant chemotherapy from January 2000 to December 2009. One hundred seventy-one HBsAg positive patients with normal baseline liver function were identified. Patients who received lamivudine before the first day of chemotherapy were regarded as lamivudine prophylaxis group and the others as non-prophylaxis group. Hepatotoxicity was assessed according to Common Terminology Criteria for Adverse Events (CTCAE, version 3.0). HBV reactivation was defined as an increase in HBV DNA levels of 10-folds or more when compared with baseline level or absolute increase of HBV DNA level that exceeded 200x 106 IU/ml or positive sero-conversion of HBV DNA. The efficacy of lamivudine prophylaxis was evaluated with grade of hepatotoxicity and HBV DNA levels during and after adjuvant chemotherapy.
Results: Of 171 patients, 70 patients received lamivudine prophylaxis and 101 patients did not. Median age of control group and study group were 45 years (range, 29-72) and 46(range, 29-67) (p=0.892). Median follow up duration was 48.5 months. Sixty-seven of 101 patients in non-prophylaxis group and 68 of 70 patients in prophylaxis group received anthracycline containing chemotherapy (p=<0.0001). Two (2.9%) patients in prophylaxis group and 13 (12.9%) patients in non-prophylaxis group experienced grade 2 or higher hepatotoxicities (p=0.027). HBV reactivation tend to occur more frequently in non-prophylaxis group compared with prophylaxis group (6.9% vs. 1.4%, p=0.143). One patient in non-prophylaxis group died of fulminant hepatitis after HBV reactivation. Interruption rate of adjuvant chemotherapy was higher in non-prophylaxis group compared with prophylaxis group (9.9% vs.1.4%, p=0.028). Among patients treated with anthracycline containing chemotherapy, the frequency of grade ≥2 hepatotoxicities (2.9% vs. 13.4%, p=0.026) was significantly higher in non-prophylaxis group; HBV reactivation (1.5% vs. 7.5%, p=0.115) tend to be higher in non-prophylaxis group. In patients receiving non-anthracycline containing chemotherapy, lamivudine prophylaxis did not make difference in hepatotoxicities or HBV reactivation.
Conclusion: Fewer hepatotoxicities occurred in lamivudine prophylaxis group with less frequent interruption of scheduled chemotherapy. Lamivudine showed tendency to reduce HBV reactivation in breast cancer patients receiving cytotoxic chemotherapy. Lamivudine prophylaxis should be considered in HBsAg positive breast cancer patients who are candidates of neoadjuvant and/or adjuvant chemotherapy.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-15-01.
Collapse
Affiliation(s)
- H-J Lee
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - JH Kim
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - S-A Im
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - D-Y Kim
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - B Keam
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - JH Lee
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - YJ Kim
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - S-W Han
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - D-Y Oh
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - S-H Jeong
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - JH Yoon
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - T-Y Kim
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - Y-J. Bang
- Seoul National University Hospital, Seoul National University College of Medicine, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| |
Collapse
|
34
|
Kim JW, Im SA, Kim JH, Ham HS, Han HS, Kim JS, Kim TM, Han SW, Oh DY, Lee SH, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Heo DS, Bang YJ. Abstract P2-09-36: Role of ABCB1 Polymorphisms as Predictive Markers in Patients with HER-2 FISH Positive Metastatic Breast Cancer Who Were Treated with Taxane Plus Trastuzumab First Line Chemotherapy. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-09-36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: ABCB1 polymorphisms could predict treatment results of taxane therapy in several malignancies. FCGR2A and FCGR3A polymorphisms were associated with clinical outcomes in several diseases after treatment with monoclonal antibody drugs which had antibody-dependent cell-mediated cytotoxicity activity. These polymorphisms could be possible predictive markers after taxane plus trastuzumab (TH) chemotherapy in patients with HER-2-positive metastatic breast cancer (MBC).
Methods: Fifty-seven patients with HER-2 FISH positive MBC who received TH chemotherapy as the 1st-line treatment were enrolled. We analyzed 5 polymorphisms using DNA from peripheral blood mononuclear cells: ABCB1 1236C>T (rs1128503), ABCB1 2677G>T/A (rs2032582), ABCB1 3435C>T (rs1045642), FCGR2A 131H/R (rs1801274), and FCGR3A 158V/F (rs396991), then correlated them to treatment results of patients.
Results: Among 57 patients, 22 patients (38.6%) received weekly paclitaxel plus trastuzumab, 26 patients (45.6%) tri-weekly paclitaxel plus trastuzumab, and 9 patients (15.8%) tri-weekly docetaxel plus trastuzumab. After a median follow-up of 30.6 (range, 0.6-75.9) months, median progression-free survival (PFS) was 15.1 (95% confidence interval (CI), 10.3-19.8) months. ABCB1 2677T allele carriers had longer PFS than the others (42.1 (95% CI, 12.7-71.4) months vs. 13.0 (95% CI, 10.6-15.4) months; p=0.037) along with a tendency toward higher response rate (RR) (86.4% vs. 76.0%; p=0.470) and longer overall survival (OS) (54.7 (95% CI, 43.0-66.4) months vs. 38.9 (95% CI, 18.1-59.7) months; p=0.057). In addition, ABCB1 3435CC genotype carriers had shorter PFS than the others (13.0 (95% CI, 10.8-15.2) months vs. 19.1 (95% CI, 0.0-38.5) months; p=0.039) along with a tendency toward lower RR (78.6% vs. 100%; p=0.567) and shorter OS (38.9 (95% CI, 19.7-58.1) months vs. 54.7 (95% CI, 43.0-66.4) months; p=0.093). ABCB1 1236C>T, FCGR2A 131H/R, and FCGR3A 158V/F were not significantly associated with RR, PFS, and OS. None of these polymorphisms were associated with any grades of hematologic or cardiac toxicities.
Conclusions: Our results support that ABCB1 2677G>T/A and 3435C>T may have predictive roles after the 1st-line TH chemotherapy in patients with HER-2-positive MBC. In contrast, ABCB1 1236C>T, FCGR2A 131H/R, and FCGR3A 158V/F could not predict response after TH treatment.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-36.
Collapse
Affiliation(s)
- J-W Kim
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - S-A Im
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - JH Kim
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - HS Ham
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - H-S Han
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - J-S Kim
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - T-M Kim
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - S-W Han
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - D-Y Oh
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - S-H Lee
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - D-W Kim
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - N Cho
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - WK Moon
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - T-Y Kim
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - IA Park
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - DS Heo
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| | - Y-J. Bang
- Seoul National University College of Medicine, Republic of Korea; Seoul National University, Republic of Korea; Public Healthcare Center of Yangyang County, Yangyang, Republic of Korea
| |
Collapse
|
35
|
Hong JY, Han SW, Kim WO, Kim EJ, Kil HK. Effect of dexamethasone in combination with caudal analgesia on postoperative pain control in day-case paediatric orchiopexy. Br J Anaesth 2010; 105:506-10. [PMID: 20659915 DOI: 10.1093/bja/aeq187] [Citation(s) in RCA: 124] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J-Y Hong
- Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Severance Hospital, 250 Seongsanno, Seodaemun-gu, 120-752 Seoul, Republic of Korea
| | | | | | | | | |
Collapse
|
36
|
Sacramento CB, Moraes JZ, Denapolis PMA, Han SW. Gene expression promoted by the SV40 DNA targeting sequence and the hypoxia-responsive element under normoxia and hypoxia. Braz J Med Biol Res 2010; 43:722-7. [PMID: 20640386 DOI: 10.1590/s0100-879x2010007500064] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2009] [Accepted: 06/30/2010] [Indexed: 11/21/2022] Open
Abstract
The main objective of the present study was to find suitable DNA-targeting sequences (DTS) for the construction of plasmid vectors to be used to treat ischemic diseases. The well-known Simian virus 40 nuclear DTS (SV40-DTS) and hypoxia-responsive element (HRE) sequences were used to construct plasmid vectors to express the human vascular endothelial growth factor gene (hVEGF). The rate of plasmid nuclear transport and consequent gene expression under normoxia (20% O2) and hypoxia (less than 5% O2) were determined. Plasmids containing the SV40-DTS or HRE sequences were constructed and used to transfect the A293T cell line (a human embryonic kidney cell line) in vitro and mouse skeletal muscle cells in vivo. Plasmid transport to the nucleus was monitored by real-time PCR, and the expression level of the hVEGF gene was measured by ELISA. The in vitro nuclear transport efficiency of the SV40-DTS plasmid was about 50% lower under hypoxia, while the HRE plasmid was about 50% higher under hypoxia. Quantitation of reporter gene expression in vitro and in vivo, under hypoxia and normoxia, confirmed that the SV40-DTS plasmid functioned better under normoxia, while the HRE plasmid was superior under hypoxia. These results indicate that the efficiency of gene expression by plasmids containing DNA binding sequences is affected by the concentration of oxygen in the medium.
Collapse
Affiliation(s)
- C B Sacramento
- Centro Interdisciplinar de Terapia Gênica, Universidade Federal de São Paulo
| | | | | | | |
Collapse
|
37
|
Lee JD, Han SW, Miyawaki N, Gomi H. Comment on "temperature-dependent localized excitations of doped carriers in superconducting diamond". Phys Rev Lett 2009; 102:199701-199702. [PMID: 19519005 DOI: 10.1103/physrevlett.102.199701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/29/2008] [Indexed: 05/27/2023]
Abstract
A Comment on the Letter by K. Ishizaka et al., Phys. Rev. Lett. 100, 166402 (2008)10.1103/PhysRevLett.100.166402. The authors of the Letter offer a Reply.
Collapse
|
38
|
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009; 100:298-304. [PMID: 19127259 PMCID: PMC2634707 DOI: 10.1038/sj.bjc.6604861] [Citation(s) in RCA: 126] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers. Patients received cetuximab 400 mg m−2 at week 1 and 250 mg m−2 weekly thereafter until disease progression. Oxaliplatin (100 mg m−2) and leucovorin (100 mg m−2) were administered as a 2-h infusion followed by a 46-h continuous infusion of 5-fluorouracil (2400 mg m−2) every 2 weeks for a maximum of 12 cycles. Biomarkers potentially associated with efficacy were analysed. Among 38 evaluable patients, confirmed response rate (RR) was 50.0% (95% CI 34.1–65.9). Median time-to-progression (TTP) was 5.5 months (95% CI 4.5–6.5) and overall survival (OS) 9.9 months. Eleven patients having tumour EGFR expression by immunohistochemistry with low serum EGF and TGF-α levels showed a 100% RR compared to 37.0% in the remaining 27 patients (P<0.001). Moreover, ligand level increased when disease progressed in seven out of eight patients with EGFR expression and low baseline ligand level. No patient exhibited EGFR amplification or K-ras mutations. Gastric cancer patients with EGFR expression and low ligand levels had better outcomes with cetuximab/mFOLFOX6 treatment.
Collapse
Affiliation(s)
- S-W Han
- Department of Internal Medicine, Seoul National University Hospital, Chongno-Gu, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Hwang C, Lee D, Han SW, Kang JS. Quantum-well states in Cu/Fe/Cu(111) coupled to the bulk band through the barrier. J Phys Condens Matter 2008; 20:265007. [PMID: 21694356 DOI: 10.1088/0953-8984/20/26/265007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The quantum-well state (QWS) has been observed on the surface of Cu/Fe/Cu(111). The confinement of the states on the top Cu layers is due to the minority spin barrier of the Fe underlayer. This QWS coexists with the Shockley surface state, which is observed on a clean Cu(111) surface. The resonant behavior of this QWS versus photon energy results from the vertical transition to the unoccupied bulk band, which is possibly due to the coupling between the overlayer Cu and the substrate Cu(111).
Collapse
Affiliation(s)
- Chanyong Hwang
- Advanced Industrial Technology Group, Division of Advanced Technology, Korea Research Institute of Standards and Science, Daejeon 305-600, Korea
| | | | | | | |
Collapse
|
40
|
Lee JD, Han SW, Inoue J. Sharp contrasts in low-energy quasiparticle dynamics of graphite between Brillouin zone K and H points. Phys Rev Lett 2008; 100:216801. [PMID: 18518624 DOI: 10.1103/physrevlett.100.216801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2007] [Indexed: 05/26/2023]
Abstract
The low-energy quasiparticle (QP) dynamics of graphite are governed by a coupling with the E(2g) longitudinal optical phonon of omega(LO) approximately 200 meV, which is found to dramatically depend on the electronic band dispersion epsilon(k). A discontinuity of the QP linewidth develops near omega(LO) for a linear band with a quadratic band top [near the Brillouin zone (BZ) K point], while it disappears for a pure linear band (near the BZ H point). It is also found that the effective electron-phonon coupling near the K point is stronger than near the H point by more than 50%. This finding makes possible a consistent understanding of recent angle-resolved photoemission observations near the K point.
Collapse
Affiliation(s)
- J D Lee
- School of Materials Science, Japan Advanced Institute of Science and Technology, Ishikawa 923-1292, Japan
| | | | | |
Collapse
|
41
|
Abstract
We describe a case of esophageal perforation that resulted from a fishbone. A 71-year-old man had had a fishbone impacted in the lower esophagus for 2 days. At presentation, the bone was dislodged at endoscopy; one round opening in a deep ulceration was detected when the fishbone was removed. The perforation was closed by endoscopic hemoclipping, after the removal of the fishbone. A thoracic computed tomography revealed air around the esophagus, aorta and bronchus and the presence of a pleural effusion. These findings suggested mediastinal emphysema and mediastinitis due to the esophageal perforation after the removal of the fishbone. Esophagography revealed a focal esophageal defect and linear contrast leakage at the distal esophagus. The mediastinal emphysema and pleural effusion successfully resolved after the endoscopic hemoclip application and conservative management of the perforation.
Collapse
Affiliation(s)
- H Y Sung
- Division of Gastroenterology, Department of Internal Medicine, Catholic University of Korea, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Helfenstein T, Ihara SSM, Santos AO, Relvas WGM, Souza DRS, Scartezini M, Han SW, Fonseca MIH, Pinto LDESA, Fonseca FAH, Izar MCO. D 003 CAN GENETIC MARKERS PREDICT CORONARY RISK IN TYPE 2 DIABETES OVER AND ABOVE CLASSIC RISK FACTORS? ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71894-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Abstract
OBJECTIVE To determine whether there is a relationship between aortic plaques and intracranial (IC) atherosclerosis. METHODS We reviewed 922 patients with stroke who had both transesophageal echocardiography and cerebral angiography. The plaques of these patients were classified as either complex aortic plaques (CAP), which protruded > or =4 mm or were present as mobile lesions in the proximal aorta, or simple aortic plaques (SAP), which were <4 mm or present in the descending aorta. Cerebral artery atherosclerosis was classified as either an IC or extracranial (EC) atherosclerosis. RESULTS Among the 922 patients, we found aortic plaques in 237 patients (26%). There were 111 (47%) patients of SAP, 74 (31%) patients with CAP, and 52 (22%) patients that had both SAP and CAP. Angiography showed IC or EC atherosclerosis in 511 patients (55%). The presence of aortic plaques was significantly associated with IC or EC atherosclerosis. The significance appeared to be due to the strong association between the presence of SAP and IC atherosclerosis (51% SAP vs 35% no plaques; odds ratio = 1.94, 95% CI: 1.17 to 3.21). In the multiple logistic regression analysis, SAP were independent predictors of IC atherosclerosis CONCLUSIONS The presence of simple aortic plaques may be a marker of advanced vascular disease. Detection of simple aortic plaques during transesophageal echocardiography may have clinical implications because patients with these plaques frequently had concomitant intracranial atherosclerosis, a risk factor for stroke.
Collapse
Affiliation(s)
- H S Nam
- Department of Neurology and National Core Research Center for Nanomedical Technology, Yonsei University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Han SW, Booth CH, Bauer ED, Huang PH, Chen YY, Lawrence JM. Lattice disorder and size-induced kondo behavior in CeAl2 and CePt(2+x). Phys Rev Lett 2006; 97:097204. [PMID: 17026397 DOI: 10.1103/physrevlett.97.097204] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2006] [Indexed: 05/12/2023]
Abstract
When the size of CeAl2 and CePt(2+x) particles is reduced to the nanometer scale, antiferromagnetism is suppressed and Kondo behavior predominates, with the Kondo temperature T(K) either decreasing (CeAl2) or increasing (CePt(2+x)) relative to the bulk. Local structure measurements show that these nanoparticles are significantly distorted. While such distortions should strongly affect magnetic and electronic properties, we find they cannot explain the observed changes in T(K). Other size-induced changes to the electronic structure must, therefore, play a significant role.
Collapse
Affiliation(s)
- S-W Han
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | | | | | | |
Collapse
|
45
|
Affiliation(s)
- S W Han
- Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
| | | | | | | | | | | |
Collapse
|
46
|
Han SW, Roman J. Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-κB. Oncogene 2006; 25:4341-9. [PMID: 16518410 DOI: 10.1038/sj.onc.1209460] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The extracellular matrix glycoprotein, fibronectin, influences a variety of cellular functions including adhesion, migration, survival, differentiation, and growth. Fibronectin has also been shown to increase the migration and proliferation of human lung carcinoma cells. However, the role of fibronectin in controlling lung airway epithelial cell phenotype remains unknown. Here, we demonstrate that fibronectin stimulates the proliferation of human bronchial epithelial cells (BEAS-2B and 16-HBE). Of note, fibronectin induced the mRNA and protein expression of c-Myc and cyclin D1, while it decreased the expressions of cyclin-dependent kinase inhibitor p21 (WAF-1/CIP1/MDA-6) (p21) and the tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten (PTEN). Fibronectin also stimulated the phosphorylation of the phosphatidylinositol 3 kinase (PI3-K) downstream signal Akt. The inhibitor of PI3-K, Wortmannin, and anti-alpha5beta1 integrin antibodies abrogated the effect of fibronectin on c-Myc, cyclin D1, p21, and PTEN expression. The stimulatory effect of fibronectin was mediated by nuclear factor kappaB (NF-kappaB) since fibronectin induced the expression of the p65 component of NF-kappaB and enhanced NF-kappaB DNA binding. Furthermore, we found that p65 small interfering RNA inhibited the effect of fibronectin on c-Myc, cyclin D1, p21, PTEN expression, and on fibronectin-induced cell proliferation. Finally, we found that fibronectin inhibits apoptosis by reducing DNA fragmentation and inhibiting the activities of caspases 3/7. Taken together, our findings demonstrate that fibronectin stimulates human bronchial epithelial cell growth and inhibits apoptosis through activation of NF-kappaB, which, in turn, increases the expression of c-Myc and cyclin D1 and decreases p21 and PTEN via alpha5beta1 integrin-dependent signals that include PI3-K/Akt. Therefore, alternations in the extracellular matrix composition of the lung, with increased fibronectin, might promote epithelial cell growth and thereby contribute to oncogenesis in certain settings.
Collapse
Affiliation(s)
- S W Han
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
| | | |
Collapse
|
47
|
Seo JS, Lee SS, Kim SI, Ryu WH, Sa KH, Kim SU, Han SW, Nam EJ, Park JY, Lee WK, Kim SY, Kang YM. Influence of VEGF gene polymorphisms on the severity of ankylosing spondylitis. Rheumatology (Oxford) 2005; 44:1299-302. [PMID: 16014410 DOI: 10.1093/rheumatology/kei013] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES To investigate the role of polymorphisms of the vascular endothelial growth factor (VEGF) gene in susceptibility to ankylosing spondylitis (AS), and their relationship to clinical features and radiographic severity. METHODS This study included 157 patients with AS and 140 healthy unrelated controls. Polymorphisms of the VEGF gene were analysed by the polymerase chain reaction (PCR)-restriction fragment length polymorphism assay and amplification refractory mutation system-PCR. Haplotypes were reconstructed using the Bayesian algorithm. Radiographic severity was assessed by the Bath Ankylosing Spondylitis Radiological Index (BASRI). RESULTS The genotype frequencies of the polymorphisms were in Hardy-Weinberg equilibrium. The distributions of genotypes and alleles did not differ between AS patients and controls. Among the six haplotypes reconstructed based on the tight linkage disequilibrium at positions -2578, -1154 and -634 (pairwise linkage disequilibrium coefficient, r = 0.361-0.706), no haplotype was associated with susceptibility to AS. Clinical features were analysed for the four haplotypes (CGC, CGG, AAG, AGG) which were prevalent. In carriers of the AGG haplotype, the frequency of cervical spine involvement was significantly higher (P = 0.002, P(corr) = 0.036) and that of patients showing a BASRI score >6 was also higher (P = 0.025, P(corr) = 0.45). CONCLUSIONS This study demonstrates that polymorphisms of the VEGF gene may contribute to disease severity in AS.
Collapse
Affiliation(s)
- J S Seo
- Department of Internal Medicine, Kyungpook National University Hospital, Samduk 2-Ga, Junggu, Daegu 700-721, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Daniel M, Bauer ED, Han SW, Booth CH, Cornelius AL, Pagliuso PG, Sarrao JL. Perturbing the superconducting planes in CeCoIn5 by Sn substitution. Phys Rev Lett 2005; 95:016406. [PMID: 16090639 DOI: 10.1103/physrevlett.95.016406] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/11/2005] [Indexed: 05/03/2023]
Abstract
In contrast to substitution on the Co or Ce site, Sn substitution has a remarkably strong effect on superconductivity in CeCoIn5-xSnx, with Tc-->0 beyond only 3.6% Sn. Instead of being randomly distributed on in-plane and out-of-plane In sites, extended x-ray absorption fine structure measurements show the Sn atoms preferentially substitute within the Ce-In plane. This result highlights the importance of the In1 site to impurity scattering and clearly demonstrates the two-dimensional nature of superconductivity in CeCoIn5.
Collapse
Affiliation(s)
- M Daniel
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
OBJECTIVE To determine whether transforming growth factor-beta1 (TGF-beta1) polymorphisms are associated with susceptibility to rheumatoid arthritis (RA) and to analyse whether they can affect the progression of radiographic severity. METHODS A total of 143 RA patients and 148 healthy unrelated controls were tested for the TGF-beta1 polymorphisms using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). RESULTS The TGF-beta1 polymorphisms were not associated with susceptibility to RA, although there was a trend that -509C/T and the 869T/C polymorphisms were associated with RA in the male population. The progression of radiographic severity, which was defined by a modified Sharp score plotted against disease duration, was significantly faster in the carrier of T allele at the -509 (p=0.048). CONCLUSION Our data support the hypothesis that TGF-beta1 polymorphism may determine the progression of joint destruction in RA.
Collapse
Affiliation(s)
- S Y Kim
- Department of Orthopaedic Surgery, Kyungpook National University School of Medicine, Daegu, South Korea
| | | | | | | | | |
Collapse
|
50
|
Relvas WGM, Izar MCO, Helfenstein T, Fonseca MIH, Colovati M, Oliveira A, Ihara SSM, Han SW, Las Casas AA, Fonseca FAH. Relationship between gene polymorphisms and prevalence of myocardial infarction among diabetic and non-diabetic subjects. Atherosclerosis 2005; 178:101-5. [PMID: 15585206 DOI: 10.1016/j.atherosclerosis.2004.05.025] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2003] [Revised: 05/04/2004] [Accepted: 05/25/2004] [Indexed: 10/26/2022]
Abstract
This study was aimed to examine cholesteryl ester transfer protein (CETP), apolipoprotein AI and CIII gene polymorphisms, and to verify whether these genetic determinants are associated with the prevalence of myocardial infarction (MI) or type 2 diabetes. The TaqIB restriction fragment length polymorphism (RFLP) in intron I of the CETP gene, the MspI in the third intron of the APOAI gene, and also SstI in the 3' untranslated region of the APOCIII gene were determined using standard methods. The prevalence of these polymorphisms was compared between diabetic (n = 119), and non-diabetic (n = 100) middle-aged individuals of both sexes. We found a higher prevalence of the B2B2 genotype of the CETP gene among diabetics than that observed in non-diabetics (P < 0.05), and a lower prevalence of this genotype among patients with previous MI (P < 0.02). The MspI polymorphisms of the APOAI gene showed that M1++ genotype was found mainly in diabetic patients (P < 0.04). Conversely, the SstI polymorphism of APOCIII gene was not significantly associated with either MI or diabetes. Therefore, among these genetic polymorphisms, TaqIB of CETP and MspI of apolipoprotein AI appeared to help significantly to identify diabetic individuals. In particular, the former may have an additional role in the primary prevention of coronary disease.
Collapse
Affiliation(s)
- W G M Relvas
- Lipides, Aterosclerose e Biologia Vascular, Disciplina de Cardiologia-Universidade Federal de São Paulo, UNIFESP, Rua Pedro de Toledo 458, São Paulo 04039-001, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|